|
Hyperglycemia-induced platelet activation in type 2 diabetes mellitus is resistant to aspirin but not to a nitric oxide-donating agent.
Diabetes Care. 2010 Mar; Epub ahead of print May
Gresele P, Marzotti S, Guglielmini G, Momi S, Giannini S, Minuz P, Lucidi P, Bolli GB, Bolli GB. |
|
Platelet JNK1 is involved in secretion and thrombus formation.
Blood. 2010 Mar;
Adam F, Kauskot A, Nurden P, Sulpice E, Hoylaerts MF, Davis RJ, Rosa JP, Bryckaert M. |
|
S-nitrosothiols as selective antithrombotic agents - possible mechanisms.
Br J Pharmacol. 2010 Mar; Epub ahead of print May
Gordge MP, Xiao F. |
|
The role of platelets in liver inflammation and regeneration.
Semin Thromb Hemost. 2010 Mar; 36(2):170-4. Epub 2010 Apr 22 May
Lisman T, Porte RJ. |
|
Toll-like receptor 2 stimulation of platelets is mediated by purinergic P2X1-dependent Ca2+ mobilisation, cyclooxygenase and purinergic P2Y1 and P2Y12 receptor activation.
Thromb Haemost. 2010 Feb; 103(2):398-407. Epub 2009 Dec 18 May
Kälvegren H, Skoglund C, Helldahl C, Lerm M, Grenegård M, Bengtsson T. |
|
The P2X1 ion channel in platelet function
Platelets. 2010 Ene; 21(3):153-66.
Hu H, Hoylaerts MF. |
|
The dual nature of extracellular ATP as a concentration-dependent platelet P2X1 agonist and antagonist
Integr Biol (Camb). 2009 Dic; 1(11-12):655-63.
Karunarathne W, Ku CJ, Spence DM. |
|
Nitric oxide inhibits von Willebrand factor-mediated platelet adhesion and spreading through regulation of integrin alpha(IIIb)beta and myosin light chain.
J Thromb Haemost. 2009 Sep; Epub ahead of print Ene
Roberts W, Michno A, Aburima A, Naseem KM. |
|
Antioxidants change platelet responses to various stimulating events.
Free Radic Biol Med. 2009 Sep; Epub ahead of print Ene
Sobotková A, Máová-Chrastinová L, Suttnar J, Stikarová J, Májek P, Reicheltová Z, Kotlín R, Weisel JW, Malý M, Dyr JE. |
|
The Many Faces Of Platelet Glycoprotein Ibalpha - Thrombin Interaction.
Curr Protein Pept Sci. 2009 Sep; Epub ahead of print Ene
Kobe B, Gun?ar G, Buchholz R, Huber T, Maco B. |
|
Platelet functions beyond hemostasis, antiplatelet therapies in high-risk patient subgroups: the Fourth Annual Platelet Colloquium.
J Thromb Thrombolysis. 2009 Abr; Epub ahead of print Abr
French PA. |
|
Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures.
Blood. 2009 Abr; Epub ahead of print Abr
Prokopi M, Pula G, Mayr U, Devue C, Gallagher J, Xiao Q, Boulanger CM, Westwood N, Urbich C, Willeit J, Steiner M, Breuss J, Xu Q, Kiechl S, Mayr M. |
|
Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.
J Biol Chem. 2009 Abr; Epub ahead of print Abr
Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W, Parrill AL, Tigyi G, Fujiwara Y. |
|
Pinning a tail on platelet thrombi.
Blood. 2009 Abr; 113(15):3395-.
Bennett JS |
|
The role of Rab38 in platelet dense granule defects.
J Thromb Haemost. 2008 Dic; 6(12):2143-51. Epub 2008 Oct 1
Ninkovic I, White JG, Rangel-Filho A, Datta YH. |
|
Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear-resistance of platelet aggregates.
J Thromb Haemost. 2008 Dic; 6(12):2193-201. Epub 2008 Oct 7
Neeves KB, Maloney SF, Fong KP, Schmaier AA, Kahn ML, Brass LF, Diamond SL. |
|
Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism.
J Thromb Haemost. 2008 Dic; 6(12):2168-74. Epub 2008 Oct 18
Abdelmalik N, Ruhé HG, Barwari K, van den Dool EJ, Meijers JC, Middeldorp S, Büller HR, Schene AH, Kamphuisen PW. |
|
Nitric oxide specifically inhibits integrin-mediated platelet adhesion and spreading on collagen.
J Thromb Haemost. 2008 Dic; 6(12):2175-85. Epub 2008 Oct 11
Roberts W, Riba R, Homer-Vanniasinkam S, Farndale RW, Naseem KM. |
|
Globular adiponectin increases cGMP formation in blood platelets independently of nitric oxide.
J Thromb Haemost. 2008 Dic; 6(12):2121-31. Epub 2008 Oct 1
Riba R, Patel B, Aburima A, Naseem KM. |
|
Equol is more active than soy isoflavone itself to compete for binding to thromboxane A(2) receptor in human platelets.
Thromb Res. 2008 Sep;
Muñoz Y, Garrido A, Valladares L. |
